The Basic Principles Of Pim-1 kinase inhibitor 4
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate various intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Key demo goals were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis